<DOC>
	<DOCNO>NCT00431782</DOCNO>
	<brief_summary>The primary purpose study ( CLN-504 ) determine safety develop dose regimen investigational anticoagulant drug ( ATI-5923 ) patient atrial fibrillation .</brief_summary>
	<brief_title>Study New Anticoagulant Drug Patients With Atrial Fibrillation</brief_title>
	<detailed_description>ATI-5923 structural analog warfarin develop oral anticoagulant . It similar pharmacological profile warfarin design provide uniform stable anticoagulation . ATI-5923 selective , non-competitive inhibitor vitamin K epoxide reductase . ATI-5923 metabolized esterase single inactive metabolite thus expect less variable metabolism , drug-drug interaction reduce instance under/over coagulation , make response safer predictable . The primary purpose study develop dose regimen INR monitoring schedule apply outpatient set safely conveniently anticoagulate patient atrial fibrillation therapeutic INR . Patients atrial fibrillation ( AF ) chosen study population trial require anticoagulation risk factor stroke .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Documented atrial fibrillation Candidate anticoagulation currently receive warfarin screen Males female great 18 year age Males females CHADS2 score 0 2 Contraindications anticoagulation e.g. , active bleeding Taking anticoagulant antiplatelet agent lowdose aspirin History myocardial infarction , acute coronary syndrome , coronary revascularization procedure within past 3 month prior Day 1 History laboratory value suggestive anemia ( i.e. , Hb &lt; 10 gm/dL ) Women childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Anticoagulation</keyword>
</DOC>